Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Age-dependent effects on the treatment response of natalizumab in MS patients.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8(+) T Cells.
Fatigue in multiple sclerosis - A brief review.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
Mesenchymal stem cells as treatment for MS - progress to date.
Substance Name: Naltrexone
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Vitamin D: a natural inhibitor of multiple sclerosis.
Nav1.5 sodium channels in macrophages in multiple sclerosis lesions.
Sexual dysfunction ın multiple sclerosis: Gender differences.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
MS related employment and disease modifying treatment in the German working population: 1994-2009.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset.
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.

Pages